Table S1 Additional information on urothelial bladder cancer patients included in the study

| Variables                      | Total    | 1993–2002 | 2003–2012 | P value |
|--------------------------------|----------|-----------|-----------|---------|
| N                              | 220,405  | 69,314    | 151,091   | <0.001  |
| Tumor site, n (%)              |          |           |           |         |
| Trigone                        | 14,035 (6.37) | 4,340 (6.26) | 9,695 (6.42) |         |
| Dome                           | 7,613 (3.45)  | 2,488 (3.59) | 5,125 (3.39) |         |
| Lateral wall                   | 45,181 (20.50) | 14,355 (20.71) | 30,826 (20.40) |         |
| Anterior wall                  | 4,383 (1.99)  | 1,302 (1.88) | 3,081 (2.04) |         |
| Posterior wall                 | 20,788 (9.43) | 6,535 (9.43) | 14,253 (9.43) |         |
| Bladder neck                   | 7,082 (3.21)  | 2,326 (3.36) | 4,756 (3.15) |         |
| Ureteric orifice               | 9,920 (4.50)  | 3,548 (5.12) | 6,372 (4.22) |         |
| Urachus                        | 34 (0.02)    | 12 (0.02)  | 22 (0.01)  |         |
| Overlapping lesion             | 24,067 (10.92)| 8,247 (11.90) | 15,820 (10.47) |         |
| Bladder, NOS                   | 87,302 (39.61)| 26,161 (37.74) | 61,141 (40.47) |         |
| T stage, n (%)                 |          |           |           | <0.001  |
| T0                             | 29 (0.01)   | 0 (0.00)   | 29 (0.02)  |         |
| Ta                             | 102,913 (46.69)| 29,398 (42.41) | 73,515 (48.66) |         |
| Tis                            | 16,444 (7.46) | 7,898 (11.39) | 8,546 (5.66) |         |
| T1                             | 52,775 (23.94)| 16,315 (23.54) | 36,469 (24.14) |         |
| ≥T2                            | 44,841 (20.34)| 14,295 (20.62) | 30,546 (20.22) |         |
| Tx                             | 3,403 (1.54) | 1,408 (2.03) | 1,995 (1.32) |         |
| N stage, n (%)                 |          |           |           | <0.001  |
| N0                             | 197,876 (89.78)| 56,327 (81.26) | 141,549 (93.68) |         |
| N1                             | 2,984 (1.35) | 332 (0.48)  | 2,652 (1.76) |         |
| N2                             | 2,574 (1.17) | 454 (0.65)  | 2,120 (1.40) |         |
| N3                             | 161 (0.07) | 42 (0.06)  | 119 (0.08)  |         |
| Nx                             | 16,810 (7.63) | 12,159 (17.54) | 4,651 (3.08) |         |
| M stage, n (%)                 |          |           |           | <0.001  |
| M0                             | 210,840 (95.66)| 66,276 (95.62) | 144,564 (95.68) |         |
| M1                             | 5,788 (2.63) | 1,641 (2.37) | 4,147 (2.74) |         |
| Mx                             | 3,777 (1.71) | 1,397 (2.02) | 2,380 (1.58) |         |
| Census region, n (%)           |          |           |           | <0.001  |
| Alaska                         | 109 (0.05) | 40 (0.06)  | 69 (0.05)  |         |
| East                           | 88,375 (40.10)| 24,982 (36.04) | 63,393 (41.96) |         |
| Northern Plains                | 22,801 (10.35)| 8,619 (12.43) | 14,182 (9.39) |         |
| Pacific Coast                  | 98,395 (44.64)| 30,940 (44.64) | 67,455 (44.65) |         |
| Southwest                      | 10,725 (4.87)| 4,733 (6.83)  | 5,992 (3.97) |         |

¹, comparison between 1993–2002 and 2003–2012. UBC, urothelial bladder cancer; NOS, not otherwise specified.
Figure S1 Kaplan-Meier curves of overall survival for urothelial bladder cancer patients in different time periods, stratified by age (A,B), gender (C,D) and T stage (E,F).
Figure S2 Kaplan-Meier curves of cancer-specific survival for urothelial bladder cancer patients in different time periods, stratified by age (A,B), gender (C,D) and T stage (E,F).